E DeJesus

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in <scp>HIV</scp>‐1‐infected treatment‐naïve patients in the <scp>ARTEMIS</scp> trial

Chloe Orkin, E DeJesus, Homayoon Khanlou et al. · HIV Medicine · 2012 · 158 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial

E DeJesus, Dennis McCarty, Charles Farthing et al. · Clinical Infectious Diseases · 2004 · 60 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

Eric Lawitz, Gary Matusow, E DeJesus et al. · Journal of Hepatology · 2015 · 59 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17